|
China is currently being vigorously develop the capital market , the number of listed companies increased rapidly in the past few years , the pharmaceutical industry as an important component of the national economy , the pharmaceutical number of listed companies with the development and growth of the capital market and the rapid increase . Although the pharmaceutical industry is an industry boom in the industry , and this high degree of economy will be in the future a very long period of time to maintain , but not all listed pharmaceutical companies can catch the industry boom and high ride the rapid growth of listed companies of the industry still is good and bad, how to determine the growth of listed companies to be of major concern to many investors believe in the value investment philosophy . In this thesis, the use of corporate growth evaluation theory and research methods , and a combination of corporate financial statements analysis theory , build pharmaceutical growth of listed companies financial statements analysis and evaluation system , aside affect the growth of enterprises complicated many internal and external factors , important data directly from a true reflection of the growth of enterprises - corporate financial statements starting from the point of view of financial statement analysis to study the growth of the pharmaceutical companies listed . Came to the conclusion by studying medicine listed companies with strong growth in financial performance : a longer period of time ( more than five years in a row ) to be able to maintain a high gross margin and the main business net profit margin , net profit mainly constituted by recurring gains and losses , net profit growth is steady , continuous main business revenue growth and net profit growth do support , there is sufficient net operating cash flow for the protection of more reasonable asset structure and capital structure, moderate leverage , there is a strong short-term solvency . Such enterprises can effectively control the business risk and financial risk , and be able to continue to improve profitability and to achieve the continuous improvement of enterprise quantity and quality , it can be judged as sound growth of medicine listed companies . Finally, case study to verify the accuracy of this view , practicality and operability . This research paper has a guiding value of many small and medium investors .
|